Editas Medicine Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
EDIT$2.51-8.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(amounts in thousands except share data)
| Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2020 | 62,563,457 | $6 | $1,058,823 | $(665,197) | $(46) | $393,586 |
| Issuance of common stock from public offering, net of issuance costs of $0.3 million | 4,025,000 | 1 | 249,458 | — | — | 249,459 |
| Issuance of common stock for repayment of notes payable | 303,599 | — | 27,500 | — | — | 27,500 |
| Exercise of stock options | 1,233,958 | — | 31,495 | — | — | 31,495 |
| Stock-based compensation expense | — | — | 43,399 | — | — | 43,399 |
| Vesting of restricted common stock awards | 267,268 | — | — | — | — | — |
| Purchase of common stock under benefits plans | 41,975 | — | 1,152 | — | — | 1,152 |
| Unrealized loss on marketable debt securities | — | — | — | — | (447) | (447) |
| Net loss | — | — | — | (192,502) | — | (192,502) |
| Balance at December 31, 2021 | 68,435,257 | $7 | $1,411,827 | $(857,699) | $(493) | $553,642 |
| Exercise of stock options | 19,769 | — | 305 | — | — | 305 |
| Stock-based compensation expense | — | — | 29,294 | — | — | 29,294 |
| Vesting of restricted common stock awards | 286,642 | — | — | — | — | — |
| Purchase of common stock under benefit plan | 105,714 | — | 979 | — | — | 979 |
| Unrealized loss on marketable debt securities | — | — | — | — | (3,108) | (3,108) |
| Net loss | — | — | — | (220,432) | — | (220,432) |
| Balance at December 31, 2022 | 68,847,382 | $7 | $1,442,405 | $(1,078,131) | $(3,601) | $360,680 |
| Issuance of common stock from public offering, net commissions, underwriting discounts and offering costs | 12,500,000 | 1 | 117,078 | — | — | 117,079 |
| Exercise of stock options | 6,587 | — | 41 | — | — | 41 |
| Stock-based compensation expense | — | — | 19,798 | — | — | 19,798 |
| Vesting of restricted common stock awards | 297,934 | — | — | — | — | — |
| Purchase of common stock under benefit plans | 115,360 | — | 919 | — | — | 919 |
| Unrealized gain on marketable debt securities | — | — | — | — | 3,799 | 3,799 |
| Net loss | — | — | — | (153,219) | — | (153,219) |
| Balance at December 31, 2023 | 81,767,263 | $8 | $1,580,241 | $(1,231,350) | $198 | $349,097 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.